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Abstract
Background: In patients with ischemic stroke of non-cardioembolic origin, acetylsalicylic acid, clopidogrel, or a
combination of acetylsalicylic acid and dipyridamole are recommended for the prevention of a recurrent
stroke. The purpose of this study was to examine the risk of bleeding or recurrent stroke associated with
these three treatments.
Methods: Patients who were discharged with first-time ischemic stroke from 2007–2010, with no history of
atrial fibrillation were identified from Danish nationwide registries. Hazard ratios (HRs) and 1-year risks of
recurrent ischemic stroke and bleeding were calculated for each antiplatelet regimen.
Results: Among patients discharged after first-time ischemic stroke, 3043 patients were treated with
acetylsalicylic acid, 12,295 with a combination of acetylsalicylic acid and dipyridamole, and 3885 with
clopidogrel. Adjusted HRs for clopidogrel versus the combination of acetylsalicylic acid and dipyridamole were
1.02 (95 % confidence interval [CI]: 0.89–1.17) for ischemic stroke and 1.06 (95 % CI: 0.83–1.35) for bleeding.
Adjusted HRs for acetylsalicylic acid versus the combination of acetylsalicylic acid and dipyridamole were 1.48
(95 % CI: 1.31–1.67) for stroke and 1.47 (95 % CI: 1.18–1.82) for bleeding. Clopidogrel versus acetylsalicylic acid
yielded HRs of 0.69 (95 % CI: 0.59–0.81) and 0.72 (95 % CI: 0.55–0.96) for stroke and bleeding, respectively.
The 1-year predicted risks associated with acetylsalicylic acid, the combination of acetylsalicylic acid and
dipyridamole, and clopidogrel were 11.1 (95 % CI: 10.2–12.2), 7.7 (95 % CI: 7.3–8.3), and 8.0 (95 % CI: 6.9–8.7)
for ischemic stroke, respectively; while, the risks for bleeding were 3.4 (95 % CI: 2.8–3.9), 2.4 (95 % CI: 2.1–2.7),
and 2.4 (95 % CI: 1.9–2.9), respectively.
Conclusion: Clopidogrel and the combination of acetylsalicylic acid and dipyridamole were associated with
similar risks for recurrent ischemic stroke and bleeding; whereas acetylsalicylic acid was associated with higher
risks for both ischemic stroke and bleeding. The latter finding may partially be explained by
selection bias.
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Background
After ischemic stroke or transient ischemia attack, pa-
tients are at high risk for a subsequent stroke. In the
Unites States, 25 % of the 795,000 annual ischemic
strokes are recurrent events [1] and 70–84 % of ischemic
stroke are non-cardioembolic [2, 3]. International guide-
lines recommend antiplatelets for secondary prevention in
patients with strokes of non-cardioembolic origin [1, 4].
The recommended treatment regimens include acetylsali-
cylic acid, a combination of acetylsalicylic acid and dipyr-
idamole, or clopidogrel.
Large-scale clinical randomized studies have evaluated
the efficacy and safety of the recommended treatments.
The combination of acetylsalicylic acid and dipyridamole
was reported to be more effective than acetylsalicylic
acid alone in preventing subsequent stroke, and may be
associated with a decreased risk of bleeding [5, 6]. In pa-
tients with ischemic stroke, no significant difference was
found between clopidogrel and acetylsalicylic acid for
the prevention of ischemic stroke/myocardial infarction
(MI)/cardiovascular (CV) death [7]. Treatment with clo-
pidogrel was as effective in preventing ischemic stroke
as the combination of acetylsalicylic acid and dipyrid-
amole, and was associated with a lower risk of bleeding
[8]. Since the combination of acetylsalicylic acid and di-
pyridamole was associated with a lower risk of recurrent
stroke than acetylsalicylic acid alone and clopidogrel was
not significantly different from acetylsalicylic acid, it was
surprising that there was no significant difference be-
tween clopidogrel and the combination of acetylsalicylic
acid and dipyridamole. This paradox may be due to dif-
ferences between study designs, such as inclusion
criteria and drug dosage [9].
Epidemiological research in a real-world cohort can
provide additional evidence of the efficacy and safety of
antiplatelet regimens, and thereby help to guide future
guidelines on therapy. Therefore, using data from
Danish nationwide registries, we investigated the risk of
recurrent stroke and bleeding in patients with ischemic
stroke from January 1st 2007 to December 31st 2010. We
compared patients treated with acetylsalicylic acid, the




Data were accessed and linked through encrypted identi-
fication numbers using registries in Statistics Denmark.
All Danish citizens carry a unique civil registration num-
ber and the registries cover the entire Danish popula-
tion. Diagnoses were found in the National Patient
Register, where diagnoses from hospital discharges are
registered according to the International Classification
of Diseases (ICD) with ICD-8 codes from 1978 and ICD-
10 codes from 1995 [10]. Information on medication
was found in the Danish Medicinal Register, where filled
prescriptions were registered since 1994 according to
the Anatomical Therapeutic Chemical (ATC) Classifica-
tion System [11]. High degree of validity for these data
has been reported previously [12]. The cause and date of
death was retrieved from the Danish Register of Causes
of Death [13].
Study population and antiplatelet therapy
All patients discharged with first-time ischemic stroke
(ICD-8: 433, 434, 436 or ICD-10: I63, I64) in the study
period from January 1st 2007-December 31st 2010 were
eligible for inclusion. Exclusion depended on the pres-
ence of the following before or up to 30 days after dis-
charge: atrial fibrillation (ICD-8 code: 42793–42794,
ICD-10: I48) at baseline or anticoagulation therapy
(ATC: B01AA, B01AE07, B01AF02, B01AF01). Acetyl-
salicylic acid was defined by ATC-code B01AC06 or
N02BA01 and clopidogrel was defined by ATC-code
B01AC04. The combination of acetylsalicylic acid and
dipyridamole was defined by either ATC-code B01AC30
or redeemed prescriptions for both acetylsalicylic acid
and dipyridamole (ATC-code B01AC07). Patients that
did not receive either acetylsalicylic acid, a combination
of dipyridamole and acetylsalicylic acid, or clopidogrel at
baseline were excluded. Acetylsalicylic acid may be sold
as an over the counter drug in Denmark, in which case
the purchase is not registered. However, prescription of
the drug is required to obtain reimbursement, which en-
ables linkage to an individual. Prescription is required
for the acquisition of dipyridamole, clopidogrel, and
glucose-lowering drugs.
Comorbidities and concomitant medication
Diabetes mellitus, heart failure, and renal disease were
defined as previously [14, 15]: diabetes mellitus by the
use of glucose-lowering drugs (ATC: A10) and heart fail-
ure (ICD-8: 425, 4270, 4271; ICD-10: I110, I42, I50,
J819) and renal disease by diagnosis (ICD-8: 24902,
25002, 40399, 58000, 58199, 582–3, 59009, 591, 75234;
ICD-10: E102, E112, E132, E142, I120, N02-8, N11-12,
N14, N18-9, N26, N158-160, N162-4, N168, Q612-3,
Q615, Q619). The discharge diagnosis prior to study in-
clusion was also used to define MI (ICD-8: 410; ICD-10:
I21, I22), peripheral artery disease (ICD-8: 440; ICD-10
DI700, I702-9), chronic obstructive pulmonary disease
(ICD-8: 491–2; ICD-10: J42-4), and cancer (ICD-8 140–
218 or ICD-10 codes C). Bleeding was defined as gastro-
intestinal bleeding (ICD-8: 53190, 53192, 53195, 53290,
53390, 53490, 53501, 56915; ICD-10: K250, K252 K254,
K256, K260, K262, K264, K266, K270, K272, K274,
K276, K920-2), intracranial hemorrhage, or bleeding
from the urogenital or respiratory system (ICD-8:
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28001,43008-9,43098-9, 431; ICD-10 I60-62, N02, R04,
R31, I690-2, J942) as done previously [15]. Hypertension
was defined by concomitant use of medication from at
least two of the following classes of antihypertensive
drugs: antiadrenergics, diuretics, vasodilators, beta-
blockers, calcium channel blockers, and renin angiotensin
converting enzyme inhibitors at baseline. This definition
of hypertension has been validated and has a specificity of
94.7 % [14, 16].
Outcomes
The following outcomes of interest were investigated:
diagnoses of fatal or nonfatal ischemic stroke and fatal
or nonfatal bleeding.
Study design
All patients with first-time ischemic stroke between
January 1st 2007 and December 31st 2010 were identi-
fied. Data on outcomes until December 31st 2011 were
available. Patients were included if they survived the first
30 days after stroke. Follow-up commenced 30 days after
discharge to allow time to redeem prescriptions, and
ended when patients experienced an outcome of inter-
est, died, emigrated, or one year after discharge, which-
ever came first.
Statistical analysis
P-values for baseline characteristics were calculated with
Chi-square test for categorical variables and Wilcoxon for
continuous variables. HR of ischemic stroke and bleeding
were calculated based on cause-specific Cox regression
analyses. These analyses were adjusted for sex, age, year,
prior myocardial infarction, hypertension, diabetes, per-
ipheral artery disease, heart failure, chronic obstructive
lung disease and cancer. The proportional hazard assump-
tion was evaluated by score process tests [17].
The absolute risks of stroke (bleeding) within 1 year
were calculated by combining the cause-specific Cox re-
gression analysis for stroke (bleeding) with a second
cause-specific Cox regression analysis for the competing
risks. The latter was adjusted for the confounders listed
above and also included the factual treatment. We pre-
dicted a personalized absolute 1-year risk of stroke
(bleeding) for each patient in counter factual data were
the treatment variable was set to acetylsalicylic acid (clo-
pidogrel, acetylsalicylic acid/dipyridamole) for all pa-
tients but keeping the factual values of all confounders.
Reported were mean 1-year risks of stroke (bleeding)
across all patients associated with acetylsalicylic acid
(clopidogrel, acetylsalicylic acid/dipyridamole) with boot-
strap confidence limits (CI) based on 200 bootstrap sam-
ples drawn with replacement from the full data. All
programming and analyses were run in SAS 9.4 (SAS
Institute Inc., Gary, NC, USA) and R 3.0.2. (R Core
Team (2013). R: A language and environment for
statistical computing. (R Foundation for Statistical
Computing, Vienna, Austria).
Ethics
Ethical approval is not required for historical register-
based studies in Denmark The study is consistent with
the Declaration of Helsinki and was approved by the
Danish Data Protection Agency (ref. 2007-58-0015, local
journal number GEH 2014–013, I-suite number 02731).
As the civil registration numbers of the patients were
encrypted, individuals could not be identified. The
authors take full responsibility for the integrity of data.
Results
Study population
A flowchart of the study population is shown in Fig. 1.
Of the 42,295 patients included after a first-time ische-
mic stroke, 19,223 remained after exclusion of patients
with atrial fibrillation, those taking oral anticoagulants,
and patients not receiving any antithrombotic treatment.
Of the included patients, 3043 were treated with acetyl-
salicylic acid, 12,295 with acetylsalicylic acid and dipyrid-
amole, and 3885 with clopidogrel. Baseline characteristics
are summarized in Table 1. Patients with acetylsalicylic
acid alone were older (median age 75.3 years, interquartile
range [IQR, 64.4–83.7]) and less often male (47.5 %) than
patients treated with the combination of acetylsalicylic
acid and dipyridamole (median age 70.7 years [IQR, 61.5–
79.6], 56.5 % males) or clopidogrel (median age 68.6 years
[IQR, 59.2–77.6], 49.3 % males). Patients receiving acetyl-
salicylic acid alone had more hypertension, renal disease,
chronic obstructive pulmonary disease, and previous
bleeding than patients treated with the combination of
acetylsalicylic acid and dipyridamole or clopidogrel. Pa-
tients treated with the combination of acetylsalicylic acid
and dipyridamole had less MIs then patients receiving
acetylsalicylic acid and clopidogrel. The median follow-up
time was 335 days [IQR, 335–335] for all treatment
groups and the total follow-up time was 2475, 10,601, and
3364 person-years for acetylsalicylic acid, combination of
acetylsalicylic acid and dipyridamole, and clopidogrel, re-
spectively. The corresponding number of ischemic strokes
was 360, 957 and 291 and the number of bleedings was
123, 286 and 92. Nine people emigrated; one person re-
ceiving clopidogrel, to receiving acetylsalicylic acid and six
on combination therapy.
Time trends in antiplatelet regimens after ischemic stroke
The proportion of patients with ischemic stroke assigned
to the different antiplatelet regimens during the study
period is shown in Fig. 2. From 2007 to 2010, the frac-
tion of patients that received acetylsalicylic acid and the
combination of acetylsalicylic acid and dipyridamole
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decreased from 19 to 12 % and from 71 to 46 %, respect-
ively; whereas, the proportion of patients that received
clopidogrel increased from 10 to 41 %.
Adherence to treatment
The adherence to the antiplatelet regimen at baseline is
shown in Table 2. The proportions of patients (alive and
event free) that adhered to the baseline antiplatelet
regimens were 86.2, 91.3, and 92.8 %/89.2 % for acetyl-
salicylic acid, clopidogrel, and acetylsalicylic acid/dipyr-
idamole, respectively.
Risk of stroke and bleeding
Adjusted HRs of ischemic stroke and bleeding are shown
in Fig. 3. No significant difference was found for clopi-
dogrel versus the combination of acetylsalicylic acid and
Fig. 1 Flowchart of study population
Table 1 Baseline characteristics
Acetylsalicylic acid Acetylsalicylic acid + dipyridamole Clopidogrel p-value
(n = 3043) (n = 12,295) (n = 3885)
Age in years, median (IQR) 75.3 (64.4–83.7) 70.7 (61.5–79.6) 68.6 (59.2–77.6) >0.0001
Men (%) 47.5 % 56.5 % 49.3 % >0.0001
Diabetes 380 (12.5 %) 1449 (11.8 %) 455 (11.7 %) 0.5263
Hypertension 1316 (43.2 %) 4987 (40.6 %) 1644 (42.3 %) 0.0102
Myocardial infarction 334 (11 %) 824 (6.7 %) 523 (13.5 %) <0.01
Peripheral artery disease 126 (4.1 %) 297 (2.4 %) 180 (4.6 %) <0.01
Heart failure 222 (7.3 %) 496 (4 %) 229 (5.9 %) <0.01
Cancer 206 (6.8 %) 714 (5.8 %) 245 (6.3 %) 0.1062
Chronic obstructive pulmonary disease 256 (8.4 %) 808 (6.6 %) 274 (7.1 %) <0.01
Previous bleeding 405 (13.3 %) 853 (6.9 %) 319 (8.2 %) <0.01
NSAIDS 485 (15.9 %) 1751 (14.2 %) 600 (15.4 %) 0.0243
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dipyridamole for stroke (HR 1.02 [95 % CI: 0.89–1.17])
or bleeding (HR 1.06 [95 % CI: 0.83–1.35]). Acetylsali-
cylic acid was associated with significantly increased
HRs for both endpoints when compared with the
combination of acetylsalicylic acid and dipyridamole,
and clopidogrel was associated with decreased HRs
for ischemic stroke and bleeding when compared with
acetylsalicylic acid.
Absolute risks of ischemic stroke and bleeding are
shown in Table 3. These results take into account the
competing risk of death for reasons other than ischemic
stroke and bleeding, and are associated with settings
where all patients would be treated with acetylsalicylic
acid (clopidogrel, acetylsalicylic acid/dipyridamole). At 3,
6, and 12 months, the risks of ischemic stroke and
bleeding were similar for clopidogrel and combination of
acetylsalicylic acid and dipyridamole. The acetylsalicylic
acid group had generally high risks of bleeding and
ischemic stroke.
Discussion
This historical register-based nationwide cohort study
comprised more than 19,000 cases of first-time ischemic
stroke without atrial fibrillation and treated with anti-
platelet regimens. The risks of ischemic stroke and
bleeding were similar for the combination of acetylsali-
cylic acid and dipyridamole and for clopidogrel; whereas,
acetylsalicylic acid alone was associated with higher risks
of both ischemic stroke and bleeding.
Acetylsalicylic acid versus the combination of
acetylsalicylic acid and dipyridamole
The European Stroke Prevention Study 2 (ESPS 2, n =
3299 with ischemic stroke or TIA within 3 months)
found that the combination of acetylsalicylic acid and di-
pyridamole was more efficient than acetylsalicylic acid
alone in preventing strokes. On the other hand, the
European/Australasian Stroke Prevention in Reversible
Ischemia Trial (ESPRIT) (n = 2739 patients with stroke or
TIA within 6 months) did not show significant reduction
in the risk of ischemic stroke or all-cause death, but did
find significantly decreased risk for the combined end-
point of ischemic stroke/MI/CV death with the combin-
ation therapy [5]. Of 1376 patients treated with the
combination of acetylsalicylic acid and dipyridamole, 470
Fig. 2 Trends in treatments after first-time ischemic stroke from 2007 through 2010: Number of cases on each antiplatelet regimen
Table 2 Adherence to baseline drugs. Proportion of patients that redeemed prescriptions for each antiplatelet treatment at 6 and
12 months after first ischemic stroke
Baseline treatment Proportion of patients that redeemed a
prescription after 6 months of baseline drug (%)
Proportion of patients that redeemed
a prescription after 12 months (%)
Clopidogrel 91.3 87.5
Acetylsalicylic acid and dipyridamole 92.8 (acetylsalicylic acid) 91.7 (acetylsalicylic acid)
89.2 (dipyridamole) 87.3 (dipyridamole)
Acetylsalicylic acid 86.0 85.6
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patients discontinued treatment, compared with 184 in
the acetylsalicylic acid group.
Bleeding was not an endpoint in ESPS 2, but similar
proportions of bleeding were reported as adverse events
in the acetylsalicylic acid and combination of acetylsali-
cylic acid and dipyridamole groups (135/1649 and 144/
1650, respectively. ESPRIT reported a decreased risk of
major bleeding (defined as intracranial bleeding, any
fatal bleeding, or bleedings requiring hospital admission)
for the combination of acetylsalicylic acid and dipyrid-
amole in the on treatment group. The investigators ex-
plained this finding as a play of chance.
Selection bias
In an observational study, there is a risk of confounding
by indication and selection bias since the study population
is not randomized at baseline. In our study the risk of
other death (other than fatal stroke) was increased in the
acetylsalicylic acid group compared with the combination
group, which indicates a difference between the two
groups. As CV death overall and not just ischemic stroke
may be influenced by antiplatelet treatment, we performed
a sensitivity analysis of the combined endpoint of stroke/
MI/CV death (data not shown), where “other death” did
not include MI or CV death and hence should not be in-
fluenced by antiplatelet treatment. However, also here the
HR of “other death” remained increased for acetylsalicylic
acid even after adjusting for comorbidity. This indicates
that treatment with acetylsalicylic acid was associated with
factors that led to poorer outcome and that this difference
was not explained by the available data on comorbid-
ity. Hence, all results regarding acetylsalicylic acid are
likely negatively biased and should be interpreted with
great care.
Clopidogrel versus acetylsalicylic acid
The Clopidogrel versus Aspirin in Patients at Risk of
Ischemic Events (CAPRIE) study included patients with
previous stroke, MI, or peripheral artery disease [7]. A
significantly decreased risk of stroke/MI/CV death was
reported for clopidogrel versus acetylsalicylic acid in the
study population overall, but no decrease in risk was
found for the sub-group analysis of patients included
after ischemic stroke. In contrast to our findings, the
higher risk of overall bleeding was not increased in
CAPRIE. This discrepancy may be explained by selection
Fig. 3 Results from cause- specific Cox regression analysis: cause-specific hazard ratios for ischemic stroke and bleeding. Other death denotes any
death other than cardiovascular death. Abbreviations: ASA = acetylsalicylic acid and DP = dipyridamole. All endpoints are adjusted for sex, age,
prior myocardial infarction, hypertension, diabetes, peripheral artery disease, heart failure, chronic obstructive lung disease, and cancer. Bleeding is
further adjusted for previous bleeding
Table 3 Predicted 1-year risk of ischemic stroke and bleeding based on Cox regression analysis













Acetylsalicylic acid 3.6 [3.2; 4.0] 6.9 [6.3;7.7] 11.1 [10.2; 12.2] 1.2 [0.9; 1.4] 2.0 [1.6; 2.4] 3.4 [2.8; 3.9]
Acetylsalicylic acid
and dipyridamole
2.4 [2.2; 2.7] 4.7 [4.4; 5.2] 7.7 [7.3; 8.3] 0.8 [0.7; 0.9] 1.4 [1.2; 1.6] 2.4 [2.1; 2.7]
Clopidogrel 2.5 [2.2; 2.9] 4.9 [4.3; 5.4] 8.0 [6.9; 8.7] 0.8 [0.6; 1.0] 1.4 [1.0; 1.7] 2.4 [1.9; 2.9]
The model was adjusted for sex, age, year, prior myocardial infarction, hypertension, diabetes, peripheral artery disease, heart failure, chronic obstructive lung
disease, and cancer
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bias, similar to what was described above for the com-
bination of acetylsalicylic acid and dipyridamole versus
acetylsalicylic acid.
Clopidogrel versus acetylsalicylic acid and dipyridamole
The finding that clopidogrel is associated with a similar
risk as the combination of acetylsalicylic acid and dipyr-
idamole for ischemic stroke and the combined endpoint
of stroke/MI/CV death is in accordance with results
from the Prevention Regimen for Effectively avoiding
Second Strokes (PRoFESS), where patients could be in-
cluded up to 120 days after the qualifying stroke (n =
20,332) [8]. PRoFESS reported no significant difference
in the risk of hemorrhagic events, but did report in-
creased risk of major bleeding (bleeding causing hospi-
talizations) in patients treated with the combination of
acetylsalicylic acid and dipyridamole compared with clo-
pidogrel recipients (HR 1.15 [95 % CI: 1.00–1.32]).
Differences in definitions of bleeding or statistical
chance may also explain the difference in results. The
network meta-analysis of ESPS2, ESPRIT, CAPRIE,
and PRoFESS addressed the apparant paradox of clo-
pidogrel being equal to the combination of acetylsalicylic
acid and dipyridamole as well as to acetylsalicylic acid,
when the combination of acetylsalicylic acid and dipyrid-
amole was superior to acetylsalicylic acid alone. The ana-
lysis concluded that the risk of recurrence stroke was not
significantly different between the three antiplatelet
regimens [9].
Strengths and limitations
The study was a register-based observational study with
built-in limitations that should be acknowledged. Due to
the risk of selection bias, the most important limitation
is that we do not have any data explaining the choice of
antiplatelets, such as intolerance. Another important
limitation is that we did not have access to data on
stroke or bleeding severity. Minor bleedings remained
unidentified in case they did not cause admissions to
hospital. Minor bleedings remained unidentified in case
they did not cause admissions to hospital. If the unregis-
tered bleedings were equally distributed between treat-
ment groups, the actual relative difference would be
smaller, while the absolute difference would not be af-
fected. In addition, we did not have data on the smoking
status, body mass index, exercise, dosage of acetylsali-
cylic acid, or the diagnoses registered by general practi-
tioners, and this may influence the results. The strengths
include the size of the study with the advantage that data
on hospitalizations and medication for the entire Danish
population were available. The registration of the diag-
nosis of stroke has a high sensitivity and specificity [18].
Generalizability
This study is representative for the Danish population and
results may plausibly apply to similar Western European
countries. In other populations with different ages, ethnic-
ities, socioeconomic and lifestyle factors, the stroke eti-
ology may differ, which may affect the impact of
antiplatelet therapy.
Implications and further studies
Our results indicate that clopidogrel or the combination
of acetylsalicylic acid and dipyridamole are equal alterna-
tives for the prevention of recurrent stroke in patients
with ischemic stroke. As noted, due to the risk of selec-
tion bias, the results regarding acetylsalicylic acid should
be interpreted with care.
Conclusion
In this nationwide study comprising more than 19,000
patients with ischemic stroke, the proportion of patients
with first time ischemic stroke that received clopidogrel
increased during the study period from 2007–2010. The
risk of secondary ischemic stroke as well as the risk of
bleeding were similar for treatment with clopidogrel and
the combination of acetylsalicylic acid and dipyridamole.
Treatment with acetylsalicylic acid alone was associated
with worse outcomes, but was not comparable to the
other groups due to risk of bias.
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